Table 3.
Seroconversion and seroprotection by subgroup analysis.
| A/H1N1 |
A/H3N3 |
B |
||||
|---|---|---|---|---|---|---|
| Subgroup | n | RR (95%CI) | n | RR (95%CI) | n | RR (95%CI) |
| Seroconversion | ||||||
| Overall | 5 | 1.34(0.91,1.98) | 3 | 1.27(0.64,2.52) | 3 | 1.19(0.97,1.46) |
| Study design | ||||||
| RCT | 4 | 1.15(0.80,1.63) | 3 | 1.27(0.64,2.52) | 3 | 1.19(0.97,1.46) |
| Cohort | 1 | 2.62(1.30,3.83) | 0 | - | 0 | - |
| Types of adjuvanted | ||||||
| MF59 | 3 | 0.95(0.77,1.17) | 3 | 1.27(0.64,2.52) | 3 | 1.19(0.97,1.46) |
| AS03 | 2 | 1.97(1.14,3.41) | 0 | - | 0 | - |
| Age | ||||||
| ≥18 | 5 | 1.34(0.91,1.98) | 3 | 1.27(0.64,2.52) | 3 | 1.19(0.97,1.46) |
| < 18 | 0 | - | 0 | - | 0 | - |
| The year of the vaccine | ||||||
| 2009 | 3 | 0.95(0.77,1.17) | 0 | - | 0 | - |
| Before 2009 | 2 | 1.97(1.14,3.41) | 3 | 1.27(0.64,2.52) | 3 | 1.27(0.64,2.52) |
| Contrast | ||||||
| Adjuvanted vs Unadjuvanted | 4 | 1.15(0.80,1.63) | 3 | 1.27(0.64,2.52) | 3 | 1.19(0.97,1.46) |
| Adjuvanted vs Unvaccinated | 1 | 2.62(1.30,3.83) | 0 | - | 0 | - |
| Seroprotection | ||||||
| Overall | 6 | 1.61(1.00,2.58) | 3 | 1.06(0.83,1.35) | 3 | 1.13(0.91,1.41) |
| Study design | ||||||
| RCT | 4 | 1.12(0.87,1.45) | 3 | 1.06(0.83,1.35) | 3 | 1.06(0.83,1.35) |
| Cohort | 2 | 1.61(1.00,2.58) | 0 | - | 0 | - |
| Types of adjuvanted | ||||||
| MF59 | 3 | 1.02(0.82,1.27) | 3 | 1.06(0.83,1.35) | 3 | 1.06(0.83,1.35) |
| AS03 | 3 | 2.52(1.18,5.37) | 0 | - | 0 | - |
| Age | ||||||
| ≥18 | 6 | 1.61(1.00,2.58) | 3 | 1.06(0.83,1.35) | 3 | 1.06(0.83,1.35) |
| < 18 | 0 | - | 0 | - | 0 | - |
| The year of the vaccine | ||||||
| 2009 | 3 | 1.02(0.82,1.27) | 0 | - | 0 | - |
| Before 2009 | 3 | 2.52(1.18,5.37) | 3 | 1.06(0.83,1.35) | 3 | 1.06(0.83,1.35) |
| Contrast | ||||||
| Adjuvanted vs. Unadjuvanted | 4 | 1.12(0.87,1.45) | 3 | 1.06(0.83,1.35) | 3 | 1.06(0.83,1.35) |
| Adjuvanted vs. Unvaccinated | 2 | 1.61(1.00,2.58) | 0 | - | 0 | - |